Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of blood cancer called AML (either newly developed or that developed from a previous blood condition).
- People who are 18 years of age or older.
- People whose AML has gone into remission (meaning no signs of the disease are visible under a microscope after treatment).
- People whose doctors have assessed them as suitable for a stem cell transplant using their own stem cells.
- People who still have detectable traces of cancer cells (known as MRD-positive) after their initial chemotherapy treatment.
- People who have a half-matched family donor available whose immune cell type (KIR-L) is incompatible with the patient's in a specific way that may be beneficial (confirm with trial site).
- People who are in generally good physical health, as measured by standard medical scoring systems (Karnofsky score of 70% or higher, or a WHO score of 2 or lower).
- People whose kidneys, lungs, and liver are all functioning at adequate levels based on blood and oxygen tests.
- People whose heart is pumping efficiently, with the left side of the heart functioning at more than 50% capacity as confirmed by an ultrasound of the heart.
- People who have read and signed a form agreeing to take part in the trial.
Who may not be able to join:
- People diagnosed with a specific subtype of AML known as FAB M3 (a particular form of the disease).
- People who are HIV positive.
- People who have hepatitis C (HCV) with a high level of the virus currently detected in their blood.
- People who are pregnant or currently breastfeeding.
- People who have an active infection that is not currently under control.
- People who are experiencing fluid build-up in the body, such as fluid around the lungs.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Antonio Curti, Istituto di Ematologia Seràgnoli, Azienda Ospedaliero-Universitaria di Bologna (IRCCS)
Phone: +390512144074
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of infusing a functional target cell dose of 2x105 alloreactive NK cells/kg in AML patients,eligible for ASCT, with persistent MRD after conventional chemotherapy; Feasibility of collecting a functional target cell dose of 2x105 alloreactive NK cells/kg in at least 70% of patients entering the study
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.